Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator
Oxytocin (OT) is a 9-amine neuropeptide that plays an essential role in mammalian labor, lactation, maternal bonding, and social affiliation. OT has been reported to exert an analgesic effect in both humans and animals, and the results of certain animal experiments have shown that the analgesic effe...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-05-01
|
Series: | Journal of Pharmacological Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861318300653 |
id |
doaj-ada2822084344d58bf01721fd9bc8ca1 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yoshiyuki Meguro Kanako Miyano Shigeto Hirayama Yuki Yoshida Naoto Ishibashi Takumi Ogino Yuriko Fujii Sei Manabe Moeko Eto Miki Nonaka Hideaki Fujii Yoichi Ueta Minoru Narita Naohiro Sata Toshihiko Yada Yasuhito Uezono |
spellingShingle |
Yoshiyuki Meguro Kanako Miyano Shigeto Hirayama Yuki Yoshida Naoto Ishibashi Takumi Ogino Yuriko Fujii Sei Manabe Moeko Eto Miki Nonaka Hideaki Fujii Yoichi Ueta Minoru Narita Naohiro Sata Toshihiko Yada Yasuhito Uezono Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator Journal of Pharmacological Sciences |
author_facet |
Yoshiyuki Meguro Kanako Miyano Shigeto Hirayama Yuki Yoshida Naoto Ishibashi Takumi Ogino Yuriko Fujii Sei Manabe Moeko Eto Miki Nonaka Hideaki Fujii Yoichi Ueta Minoru Narita Naohiro Sata Toshihiko Yada Yasuhito Uezono |
author_sort |
Yoshiyuki Meguro |
title |
Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |
title_short |
Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |
title_full |
Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |
title_fullStr |
Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |
title_full_unstemmed |
Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |
title_sort |
neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |
publisher |
Elsevier |
series |
Journal of Pharmacological Sciences |
issn |
1347-8613 |
publishDate |
2018-05-01 |
description |
Oxytocin (OT) is a 9-amine neuropeptide that plays an essential role in mammalian labor, lactation, maternal bonding, and social affiliation. OT has been reported to exert an analgesic effect in both humans and animals, and the results of certain animal experiments have shown that the analgesic effect of OT is partially blocked by opioid receptor antagonists. To investigate the relationship between OT and μ opioid receptor (MOR), we evaluated how OT affects MOR in vitro by performing an electrical impedance-based receptor biosensor assay (CellKey™ assay), an intracellular cAMP assay, and a competitive receptor-binding analysis by using cells stably expressing human MOR and OT receptor. In both the CellKey™ assay and the intracellular cAMP assay, OT alone exerted no direct agonistic effect on human MOR, but treatment with 10−6 M OT markedly enhanced the MOR signaling induced by 10−6 M endomorphin-1, β-endorphin, morphine, fentanyl, and DAMGO. Moreover, in the competitive receptor-binding assay, 10−6 M OT did not alter the affinity of endomorphin-1 or morphine for MOR. These results suggest that OT could function as a positive allosteric modulator that regulates the efficacy of MOR signaling, and thus OT might represent a previously unrecognized candidate analgesic agent. Keywords: Oxytocin, μ opioid receptor, Positive allosteric modulator, Analgesia, G protein-coupled receptor (GPCR) |
url |
http://www.sciencedirect.com/science/article/pii/S1347861318300653 |
work_keys_str_mv |
AT yoshiyukimeguro neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT kanakomiyano neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT shigetohirayama neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT yukiyoshida neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT naotoishibashi neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT takumiogino neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT yurikofujii neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT seimanabe neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT moekoeto neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT mikinonaka neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT hideakifujii neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT yoichiueta neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT minorunarita neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT naohirosata neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT toshihikoyada neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator AT yasuhitouezono neuropeptideoxytocinenhancesmopioidreceptorsignalingasapositiveallostericmodulator |
_version_ |
1725326218490806272 |
spelling |
doaj-ada2822084344d58bf01721fd9bc8ca12020-11-25T00:30:33ZengElsevierJournal of Pharmacological Sciences1347-86132018-05-0113716775Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulatorYoshiyuki Meguro0Kanako Miyano1Shigeto Hirayama2Yuki Yoshida3Naoto Ishibashi4Takumi Ogino5Yuriko Fujii6Sei Manabe7Moeko Eto8Miki Nonaka9Hideaki Fujii10Yoichi Ueta11Minoru Narita12Naohiro Sata13Toshihiko Yada14Yasuhito Uezono15Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Surgery, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, JapanDivision of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, JapanDepartment of Medicinal Chemistry, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, JapanDivision of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba, 278-8510, JapanDivision of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Medicinal Chemistry, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, JapanDivision of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Medicinal Chemistry, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, JapanDivision of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, JapanDivision of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Anesthesiology and Resuscitation, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, Okayama, 700-8558, JapanDivision of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba, 278-8510, JapanDivision of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, JapanDepartment of Medicinal Chemistry, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, JapanDepartment of Physiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku Kitakyushu, Fukuoka, 807-8555, JapanDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan; Life Science Tokyo Advanced Research Center (L-StaR), Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, JapanDepartment of Surgery, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, JapanDivision of Integrative Physiology, Department of Physiology, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, JapanDivision of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Division of Supportive Care Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Comprehensive Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan; Corresponding author. Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.Oxytocin (OT) is a 9-amine neuropeptide that plays an essential role in mammalian labor, lactation, maternal bonding, and social affiliation. OT has been reported to exert an analgesic effect in both humans and animals, and the results of certain animal experiments have shown that the analgesic effect of OT is partially blocked by opioid receptor antagonists. To investigate the relationship between OT and μ opioid receptor (MOR), we evaluated how OT affects MOR in vitro by performing an electrical impedance-based receptor biosensor assay (CellKey™ assay), an intracellular cAMP assay, and a competitive receptor-binding analysis by using cells stably expressing human MOR and OT receptor. In both the CellKey™ assay and the intracellular cAMP assay, OT alone exerted no direct agonistic effect on human MOR, but treatment with 10−6 M OT markedly enhanced the MOR signaling induced by 10−6 M endomorphin-1, β-endorphin, morphine, fentanyl, and DAMGO. Moreover, in the competitive receptor-binding assay, 10−6 M OT did not alter the affinity of endomorphin-1 or morphine for MOR. These results suggest that OT could function as a positive allosteric modulator that regulates the efficacy of MOR signaling, and thus OT might represent a previously unrecognized candidate analgesic agent. Keywords: Oxytocin, μ opioid receptor, Positive allosteric modulator, Analgesia, G protein-coupled receptor (GPCR)http://www.sciencedirect.com/science/article/pii/S1347861318300653 |